An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies

Trial Profile

An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Ixazomib (Primary)
  • Indications Amyloidosis; Lymphoma; Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 04 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 01 Nov 2016 Planned initiation date changed from 1 Oct 2016 to 1 Dec 2016.
    • 07 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top